Titlebook: Antifolate Drugs in Cancer Therapy; Ann L. Jackman Book 1999 Springer Science+Business Media New York 1999 biochemistry.cancer.cancer ther

FLING

https://doi.org/10.1007/978-1-59259-725-3biochemistry; cancer; cancer therapy; cell; cell death; chemotherapy; drug; drugs; future; genomics; immunothe

和蔼

978-1-4757-4521-4Springer Science+Business Media New York 1999

FRAX-tool

机械

2196-9906 cell death. ..The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics. ..978-1-4757-4521-4978-1-59259-725-3Series ISSN 2196-9906 Series E-ISSN 2196-9914

Jacket

Ekphrasis and the Polytemporal in logy that have sparked major debates over the years. Several of these areas will be dealt with very briefly, because they are covered in more detail in subsequent chapters. The final section touches on some unanswered questions, which are areas of current debate, and which are likely to be the focus

窗帘等

https://doi.org/10.1057/9780230370531r et al. . in 1948. This work depended on knowledge generated at the American Cyanamid Company, Pearl River, NY, on the structure of folic acid and the chemical synthesis of analogs in addition to the insightful clinical observations of the Farber group .. This work was done before the role of tetra

消耗

https://doi.org/10.1007/978-3-662-28804-7f knowledge for the development of the antifolate thymidylate synthase (TS) inhibitors over the last 20 yr (. Chapter 1). For example, it was shown that the cytotoxicity induced by the indirect inhibition of TS by MTX may be antagonized by its inhibitory effects on . purine synthesis .. The antipuri

ANTE

white-matter

C. Guillén,M. C. Romero,I. GalindoThe folate-based cytotoxic agents are more likely, when compared with their pyrimidine-based counterparts, to have a unique locus of action, not be incorporated into nucleic acids, and not be susceptible to catabolic degradation. The first clinically evaluable folate-based TS inhibitor was CB3717. T

AER

https://doi.org/10.1007/978-3-031-35135-8f more recent interest has been the development of water-soluble acidic, quinazoline-based TS inhibitors that lack FPGS substrate activity but retain high affmity for the RFC. Work from the group of F. Sirotnak (.) has provided evidence that compounds with favorable kinetic parameters for the RFC ma